Oral Thrombin Inhibitor Ximelagatran given to Patients as Prolonged Prophylaxis after a Six-month Anticoagulation Treatment for Venous Thromboembolism. An International Multicentre Double-blind Placebo Controlled Study (THRIVE III)

Study identifier:SH-TPV-0003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Oral Thrombin Inhibitor Ximelagatran given to Patients as Prolonged Prophylaxis after a Six-month Anticoagulation Treatment for Venous Thromboembolism. An International Multicentre Double-blind Placebo Controlled Study (THRIVE III)

Medical condition

venous thromboembolism

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Nov 1999
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria